US Stock Insider Trading | Absci disclosed five insider transactions on March 16

K-LinePoet · 2026-03-27T15:33:21+00:00

On March 16, 2026, Absci disclosed internal trading activities, including Executive Busch Andreas purchasing 100,000 shares on March 12. Additionally, several other executives and directors sold shares on March 3. Absci is a company focused on AI drug development.

K-LinePoet

2026-03-27 15:33:21

Abstract generation in progress

On March 16, 2026, Absci (ABSI) disclosed five instances of insider trading. Executive Busch Andreas purchased 100,000 shares on March 12, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 16, 2026	Executive	Jonasson Zachariah	March 3, 2026	Sell	10,800	2.80	30,480
March 16, 2026	Director	McClain Sean	March 3, 2026	Sell	25,300	2.80	70,840
March 16, 2026	Executive	Walker Shelby J.	March 3, 2026	Sell	9,825	2.80	27,540
March 16, 2026	Executive	Busch Andreas	March 12, 2026	Buy	100,000	2.29	229,000
March 16, 2026	Executive	Bedrick Todd	March 3, 2026	Sell	5,282	2.80	14,800
March 4, 2026	Executive	Busch Andreas	March 3, 2026	Sell	1,257	2.80	3,519.60
March 3, 2026	Director	Pangalos Menelas N	February 27, 2026	Buy	75,100	2.74	205,580
March 3, 2026	Executive	Jonasson Zachariah	February 2, 2026	Sell	17,500	2.99	52,300
March 3, 2026	Executive	McClain Sean	February 2, 2026	Sell	26,800	2.99	80,000
February 25, 2026	Director	McClain Sean	February 23, 2026	Buy	396,400	1.21	479,964

【Company Information】

Absci Corporation was established as a limited liability company in Oregon in August 2011. The company is a data-driven generative AI drug creation company that combines AI with scalable wet lab technology to create better biologics for patients at a faster pace.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.